MASI
Masimo Corp
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
masimo (nasdaq: masi) is a global medical technology company that develops and manufactures innovative noninvasive patient monitoring technologies, including medical devices and a wide array of sensors. our work is making a measurable difference in the world by saving, extending and improving the lives of people of all ages, in all walks of life for more than 27 years, our innovative medical technologies and noninvasive patient monitoring solutions have been solving ‘unsolvable’ problems. the result is a portfolio of clinically-proven products that lead the way in innovation, performance and patient safety by giving health care providers the information they need to optimize clinical decision-making. masimo is for‘what-ifers’, ‘never-say-never-ers’, and ‘world changers’—people who look beyond what others see. we're looking for people who can, do, and will make a difference. we think you'll like what you see.
Market Cap: 6.86 Billion
Primary Exchange: NASDAQ
Website: https://www.masimo.com/
Shares Outstanding: 52.9 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 0.6552344052791965
Sector: Manufacturing
Industry: Electromedical and Electrotherapeutic Apparatus Manufacturing
Ethical Flags
Longest drawdown: 716 trading days
From: 2021-11-19 To: 2024-03-07
Lowest Point:
Masimo Announces FDA Clearance of Neonatal Indication for O3® Regional Oximetry
via: Business Wire at 2019-06-10 04:00:00:000
Masimo (NASDAQ: MASI) announced today that O3 Regional Oximetry has received FDA clearance for use on neonatal and infant patients (<10 kg). O3 may help clinicians monitor cerebral oxygenation in situations in which peripheral pulse oximetry alone may not be fully indicativ… read more...
Masimo Announces FDA Clearance of Neonatal Indication for O3® Regional Oximetry
via: Business Wire at 2019-06-10 04:00:00:000
Masimo (NASDAQ: MASI) announced today that O3 Regional Oximetry has received FDA clearance for use on neonatal and infant patients (<10 kg). O3 may help clinicians monitor cerebral oxygenation in situations in which peripheral pulse oximetry alone may not be fully indicativ… read more...
Masimo Announces FDA Clearance of Neonatal Indication for O3® Regional Oximetry
via: Business Wire at 2019-06-10 04:00:00:000
Masimo (NASDAQ: MASI) announced today that O3 Regional Oximetry has received FDA clearance for use on neonatal and infant patients (<10 kg). O3 may help clinicians monitor cerebral oxygenation in situations in which peripheral pulse oximetry alone may not be fully indicativ… read more...
Masimo Announces FDA Clearance of Neonatal Indication for O3® Regional Oximetry
via: Business Wire at 2019-06-10 04:00:00:000
Masimo (NASDAQ: MASI) announced today that O3 Regional Oximetry has received FDA clearance for use on neonatal and infant patients (<10 kg). O3 may help clinicians monitor cerebral oxygenation in situations in which peripheral pulse oximetry alone may not be fully indicativ… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|